GE HealthCare Technologies Inc.
NASDAQ:GEHCMedical - Healthcare Information Services
+$0.45 today
- Market cap
- $37.83B
- Beta
- 0.86
- P/E (TTM)
- 18.7
- EPS (TTM)
- $3.30
- Dividend yield
- 0.23%
Volume 3.65M
Average 4.84M
GEHC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
GE HealthCare Technologies Inc.NASDAQ: GEHC
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $323M rose 7.0% year over year, ahead of the +1.2% change in trailing-twelve-month research & development. Sequentially, it fell 6.4% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Research & development amounted to 6.1% of revenue in FY2025, down 0.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +7.0% holds above the trailing-twelve-month pace of +1.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.26B USD
- Year-over-year change
- -3.9%
- 4-year CAGR
- +11.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.26B | -3.9% |
| FY2024 | 2024-12-31 | 1.31B | +8.8% |
| FY2023 | 2023-12-31 | 1.21B | +17.4% |
| FY2022 | 2022-12-31 | 1.03B | +25.7% |
| FY2021 | 2021-12-31 | 816M | — |
Research & Development vs competitors
How GEHC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.2% is the 5th highest of 6, against a peer median of +10.1%.
- Research & development amounts to 6.5% of revenue for GEHC, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.28B USD | +11.3% | +1.2% | 6.8% | |
| LTM Jul 2026 | $2.92B USD | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B USD | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | €1.72B EUR | -2.6% | -6.7% | 9.7% | |
| LTM Jun 2026 | $1.66B USD | +10.1% | +8.8% | 6.4% | |
| LTM Jun 2026 | $1.32B USD | +1.2% | +7.1% | 6.5% | |
| Peer median (excluding GEHC) | — | +10.1% | +2.1% | 7.8% | |
Competitors are the stored peer set for GEHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.59B | 18.34B | 19.55B | 19.67B | 20.63B |
| Cost of Revenue | 10.41B | 11.16B | 11.63B | 11.47B | 12.38B |
| Gross Profit | 7.17B | 7.18B | 7.92B | 8.21B | 8.25B |
| Gross Margin | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% |
| Research & Development | 816M | 1.03B | 1.21B | 1.31B | 1.26B |
| Selling, General & Admin | 3.56B | 3.63B | 4.28B | 4.27B | 4.23B |
| Operating Expenses | 4.38B | 4.66B | 5.49B | 5.58B | 5.49B |
| Depreciation & Amortization | 625M | 633M | 610M | 580M | 578M |
| EBITDA | 3.54B | 3.17B | 3.51B | 3.67B | 3.79B |
| EBITDA Margin | 20.1% | 17.3% | 18.0% | 18.6% | 18.4% |
| Operating Income | 2.8B | 2.52B | 2.44B | 2.63B | 2.76B |
| Operating Margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% |
| Interest Income | 34M | 0 | 26M | 0 | 0 |
| Interest Expense | 40M | 86M | 542M | 505M | 450M |
| Other Income / Expenses | 80M | (10M) | (74M) | (44M) | 6M |
| Income Before Tax | 2.88B | 2.51B | 2.36B | 2.58B | 2.77B |
| Pre-Tax Margin | 16.3% | 13.7% | 12.1% | 13.1% | 13.4% |
| Income Tax Expense | 600M | 563M | 743M | 531M | 614M |
| Net Income | 2.25B | 1.92B | 1.57B | 1.99B | 2.08B |
| Net Margin | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% |
| EPS (Basic) | 4.90 | 4.22 | 3.04 | 4.37 | 4.56 |
| EPS (Diluted) | 4.90 | 4.22 | 3.02 | 4.34 | 4.55 |
| Weighted Avg Shares | 454.71M | 453.93M | 455M | 456M | 456.52M |
| Weighted Avg Shares (Diluted) | 454.71M | 453.93M | 458M | 459M | 460.27M |
GE HealthCare Technologies Inc.
NASDAQ:GEHC
Intrinsic Alpha fair value
Locked
Current Price
$83.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.